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Non-alcoholic fatty liver disease (NAFLD) is the most common
cause of chronic liver disease in Western countries that is pre-
dicted to become also the most frequent indication for liver
transplantation by 2030. Over the last decade, it has been shown
that the clinical burden of NAFLD is not only conﬁned to liver-re-
lated morbidity and mortality, but there is now growing evidence
that NAFLD is a multisystem disease, affecting extra-hepatic
organs and regulatory pathways. For example, NAFLD increases
risk of type 2 diabetes mellitus (T2DM), cardiovascular (CVD)
and cardiac diseases, and chronic kidney disease (CKD).
Although the primary liver pathology in NAFLD affects hepatic
structure and function to cause morbidity and mortality from cir-
rhosis, liver failure and hepatocellular carcinoma, the majority of
deaths among NAFLD patients are attributable to CVD. This nar-
rative review focuses on the rapidly expanding body of clinical
evidence that supports the concept of NAFLD as a multisystem
disease. The review discusses the factors involved in the progres-
sion of liver disease in NAFLD and the factors linking NAFLD with
other extra-hepatic chronic diseases, such as T2DM, CVD, cardiac
diseases and CKD. The review will not discuss NAFLD treatmentsJournal of Hepatology 20
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this review, PubMed was searched for articles using the keywords
‘‘non-alcoholic fatty liver disease’’ or ‘‘fatty liver’’ combined with
‘‘diabetes’’, ‘‘cardiovascular (or cardiac) disease’’, ‘‘cardiovascular
mortality’’ or ‘‘chronic kidney disease’’ between 1990 and 2014.
Articles published in languages other than English were excluded.
 2014 European Association for the Study of the Liver. Published
by Elsevier B.V. Open access under CC BY-NC-ND license.Introduction
Over the last decade, it has been shown that the clinical burden of
non-alcoholic fatty liver disease (NAFLD) is not only conﬁned to
liver-related morbidity and mortality, but there is now growing
evidence that NAFLD is a multisystem disease, affecting several
extra-hepatic organs and regulatory pathways [1]. Since NAFLD
has become the predominant cause of chronic liver disease in
many parts of the world [2], NAFLD is also potentially contribut-
ing to an important burden of extra-hepatic chronic complica-
tions. For reasons that are not completely clear, NAFLD is more
common in men than women and although precise estimates of
incidence rates for NAFLD are uncertain (because of difﬁculties
with establishing a precise diagnosis during sequential follow-
up), current incidence rates are approximately 20/10,000 person-
years, peaking in the sixth decade of life [3]. Current population-
based prevalence of NAFLD is approximately 30–40% in men and
15–20% in women [4] and is even higher in people with type 2
diabetes mellitus (T2DM), occurring in up to 70% of this group
of patients [5].
A major focus of the NAFLD-related chronic diseases during
the last 10 years has involved chronic liver disease, cardiovascu-
lar disease (CVD) and T2DM; e.g., a recent meta-analysis showed
that NAFLD increased overall mortality by 57% mainly from liver-
related and CVD causes, and increased risk of incident T2DM by
approximately twofold [6]. Additionally, and even more recently,
increasing attention has also focused on NAFLD-related chronic
kidney disease (CKD) and a further recent meta-analysis reported
that NAFLD was associated with an approximate twofold
increased risk of CKD [7]. Although there is also emerging evi-
dence that NAFLD is linked to other chronic diseases, such as
sleep apnea, colorectal cancers, osteoporosis, psoriasis and var-
ious endocrinopathies (e.g., polycystic ovary syndrome) [8],
because of the limitations on space, this review will focus only15 vol. 62 j S47–S64
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on NAFLD-related extra-hepatic diseases where there is strongest
evidence for a possible causal link between NAFLD and pathology
in extra-hepatic organs (namely T2DM, CVD and CKD).
This narrative review will discuss NAFLD and: a) liver disease
that is relevant to the development of extra-hepatic complica-
tions, b) T2DM, c) CVD and cardiac diseases, and d) CKD. The aeti-
ology and pathogenesis of each of these hepatic and extra-hepatic
chronic complications will also be brieﬂy discussed.
Key Points
• Liver fat accumulation in NAFLD increases risk of type 2
diabetes mellitus approximately twofold  
• Hepatic lipid accumulation (e.g., di-acyl glycerol) in
NAFLD impairs insulin signaling (insulin resistance) that
contributes to abnormal hepatic metabolism
• Increasing evidence suggests more severe forms of
NAFLD further increase risk of type 2 diabetes mellitus
• Both NASH and type 2 diabetes mellitus increase risk of
hepatocellular carcinoma 
• Mechanisms contributing to the pathogenesis of 
hepatocellular carcinoma also occur with obesity and
insulin resistance (i.e., two common risk factors for type
2 diabetes mellitus)
• Increasing evidence indicates that the presence and
severity of NAFLD is associated with an increased
prevalence and incidence of cardiovascular disease,
independently of established cardiovascular risk factors
• Some evidence also indicates that the presence and
severity of NAFLD is associated with an increased
prevalence and incidence of chronic kidney disease,
independently of multiple cardio-renal risk factors
• It is now becoming increasingly evident that NAFLD
is not simply a marker of cardiovascular disease and
chronic kidney disease, but also may play a part 
in the pathogenesis of these extra-hepatic chronic
complications
• The clinical implication for these findings is that NAFLD
patients may benefit from more intensive surveillance
and early treatment interventions to decrease the risk
for cardiovascular and kidney complicationsNAFLD: diagnosis, development, and progression of liver
disease
In clinical practice, an initial diagnosis of NAFLD is usually estab-
lished with radiological imaging techniques, by the presence of
P5% hepatic fat accumulation in the absence of other recognized
causes of fatty liver, e.g., alcohol, virus, drugs, autoimmunity.
Because of the limitations of space, this reviewwill not discuss
the use of the various techniques for diagnosing NAFLD. However,
for a detailed recent review of the radiological imaging modalities
available for the assessment of NAFLD see [9]; for more detailsS48 Journal of Hepatology 201regarding the sensitivity and speciﬁcity of ultrasonography to
detect liver fat, the reader is referred to the following [10–12];
and for information, regarding the sensitivity and reproducibility
of magnetic resonance techniques to assess liver fat [13,14]. For a
discussion of the utility of histological characterization of the liv-
er, using a designated scoring system, see [11,15].
NAFLD is fast becoming one of the most common causes of
chronic liver disease worldwide, and is now a major cause of liv-
er-related morbidity and mortality [16]. NAFLD begins with liver
lipid accumulation, and marked hepatic fat accumulation is a risk
factor for disease progression. Although the major risk factors for
hepatic fat and hepatic ﬁbrosis development in NAFLD are well
established (e.g., age >50 years, obesity, insulin resistance,
T2DM, increased ferritin levels and the patatin-like phospholi-
pase domain-containing 3 (PNPLA3) I148M polymorphism) [17–
19], the pathological mechanisms by which each of these risk fac-
tors (particularly PNPLA3 genotype) cause NAFLD progression are
less well understood. It has been shown that when associated
with the I148M gene variant, NAFLD has a lower plasma triacyl-
glycerol proﬁle. This supports the notion that the I148M gene
variant inhibits intra-hepatocellular lipolysis rather than stimu-
lates hepatic triacylglycerol synthesis [20]. However, further
work is required to establish the precise function of PNPLA3 in
the pathogenesis of liver disease progression in NAFLD, as it has
also been highlighted in response to this work that a contribution
of PNPLA3 lysophosphatidic acid acyltransferase activity could
also contribute to altered plasma triacylglycerol composition
and concentration [21]. Where there is evidence of advanced
hepatic ﬁbrosis, which is easier to establish with some of the
newer non-invasive imaging modalities [9,22], complications
such as cirrhosis and hepatocellular carcinoma (HCC) are not
uncommon. Development of hepatic ﬁbrosis occurs in 40–50%
of patients with non-alcoholic steatohepatitis (NASH) and current
estimates are that approximately 30–40% of people with NAFLD
develop NASH [23]. From a meta-analysis of 40 studies, it has
been estimated that NASH increases the risk of liver-related mor-
tality by 5–10 fold (mainly depending on the degree of hepatic
ﬁbrosis present) [6]. With regard to this, Ekstedt et al. recently
conﬁrmed that hepatic ﬁbrosis stage was the strongest predictor
for all-cause and disease-speciﬁc mortality in patients with histo-
logically conﬁrmed NAFLD, who were followed-up for a mean
period of 26.4 years [24]. In 2009, patients with NASH accounted
for 10% of patients undergoing liver transplantation in the
United States; NASH is the third most common indication for liv-
er transplantation in the United States, and considering the spec-
trum of disease encapsulated within NAFLD, NAFLD is on a
trajectory to become the most common indication for liver trans-
plantation [25].
It has been known for many years that obesity and T2DM
increase the risk of HCC [26] but the biological explanation for
this link remains uncertain. NASH is common in patients with
obesity, insulin resistance and T2DM and NASH increases the risk
of HCC [27]. That said, it is uncertain whether there is a diabetes/
obesity-speciﬁc factor that increases risk of HCC or whether there
are common pathological mechanisms that occur both in HCC
and in T2DM/obesity. For HCC, it has been recently shown that
incidence and mortality rates have increased approximately two-
fold in men and women between 1968 and 2008 [28,29].
Although it is less certain whether simple steatosis increases risk
of HCC, it is now becoming clear that NASH is a risk factor for
HCC, even in people without cirrhosis [30–32].5 vol. 62 j S47–S64
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The underlying mechanisms by which NASH or T2DM
increase risk of developing HCC are not completely understood,
but mechanisms involved in liver inﬂammation, metabolic stress
and insulin resistance that are shared between NASH and T2DM
may be also involved in HCC development. Activation of certain
metabolic or stress-response pathways, involving one-carbon
metabolism, nuclear factor-kappa B (NF-jB), phosphatase and
tensin homolog (PTEN), and microRNAs occur with HCC [33].
Many of these pathways involved in causing cellular stress also
occur within tissues affected by obesity and insulin resistance
[34], which are commonly linked and important in the patho-
genesis of T2DM. It also has been suggested that chronic activa-
tion of toll-like receptor 4 (TLR-4) (i.e., an upstream activator of
NF-jB signaling [35]) by gut microbiota-derived ligands, such
as lipopolysaccharide may occur. Additionally, gut microbiota-
mediated metabolism of bile acids has recently been implicated
in HCC development [36]. Gut microbiota also metabolize prima-
ry bile acids produced by the liver to secondary bile acids such as
deoxycholic acid. In a mouse model of HCC, when deoxycholic
acid production was blocked by an inhibitor, HCC development
was suppressed [36], implicating the interaction between the
gut microbiota and bile production in the pathogenesis of HCC
(Fig. 1).
Indeed, the possibility that alterations in the gut microbiota
that promote the development of T2DM and NAFLD, and that
induce increased risk of HCC, make the gut microbiota an attrac-
tive and potentially new therapeutic target in NAFLD (and possi-
bly too in T2DM where there is obesity and insulin resistance).
We and others are testing the effects of synbiotic treatment (a
combined pro- and pre-biotic therapeutic agent) in NAFLD
patients (see INvestigation of SYnbiotic TrEatment (INSYTE) in
Non-Alcoholic Fatty Liver Disease (NAFLD), www.clinicaltri-
als.gov Registration number NCT 01680640). It is likely that fur-
ther research over the next few years will clarify whether
therapeutic modiﬁcation of the gut microbiota is therapeutically
desirable in reducing the development of liver fat and inﬂamma-
tion in the early stages of NAFLD. However, whether therapeutic
modiﬁcation of the gut ﬂora decreases complications of NAFLD
such as cirrhosis and HCC will take longer to establish.NAFLD and diabetes: epidemiology
It has been known for many years that there is a substantial
increased risk of mortality from cirrhosis of any aetiology in
patients with T2DM [26,37], but the explanation for this increase
in risk remains uncertain. Using a large electronic administrative
database, we recently analyzed all information available in death
certiﬁcates in an entire region in Italy to investigate the aetiology
of chronic liver disease-associated mortality in people with dia-
betes (n = 167,621 diabetic individuals aged 30–89 years).
Notably, we found that diabetic individuals had an approximately
threefold higher risk of dying of chronic liver diseases, mainly
associated with a non-virus and non-alcohol-related aetiology,
which is largely attributable to NAFLD [38].
Some studies that have examined the relationship between
NAFLD and T2DM have used simple biochemical and anthropo-
metric measures as proxies for NAFLD. Serum levels of alanine
transaminase (ALT) and gamma-glutamyltransferase (GGT) or
the NAFLD fatty liver score and the fatty liver index, which are
generated from anthropometric and biochemical measurementsJournal of Hepatology 201have been used as markers for NAFLD, and single biochemical
tests are not good markers for assessing NAFLD severity or for
guiding clinical management decisions [39]. With that caveat,
and, as illustrated by recent work from France, studies that have
used biochemical markers as proxies for NAFLD have shown that
NAFLD is associated with incident T2DM, independently of mul-
tiple potential confounding factors [40]. However, because it is
difﬁcult to be certain that abnormal liver function tests are mark-
ers for NAFLD, we have excluded studies that have only used bio-
chemical or anthropometric parameters to diagnose NAFLD from
this review, since it is often not possible to prove that these sub-
jects had NAFLD. For example, evidence is showing that serum
GGT level in particular is a marker of oxidative stress rather than
a speciﬁc marker of NAFLD-induced liver disease [41].
Among the studies that have used non-invasive imaging tech-
niques (predominantly ultrasonography) to diagnose NAFLD and
that have assessed the risk of developing T2DM [42–52], nearly
all have shown that NAFLD increases substantially the risk of
incident T2DM. As summarized in Table 1, risk of T2DM among
these studies varied markedly from a 64% increase [50] to a
5.5-fold increase in risk [44]. This wide inter-study variation in
risk might reﬂect differences in NAFLD severity, since the study
by Park et al. [49] showed that the incidence rate of T2DM
increased progressively according to the ultrasonographic sever-
ity of NAFLD at baseline (normal: 7.0%, mild: 9.8%, moderate-to-
severe: 17.8%, p <0.001). Even after adjusting for multiple con-
founders, the hazard ratios (HRs) for T2DM development were
signiﬁcantly higher in the mild-NAFLD group (HR 1.09; 95% CI
0.81–1.48) and in the moderate-to-severe NAFLD group (1.73;
1.00–3.01) than in the no-NAFLD group, respectively.
Additionally, the wide inter-study variation in risk of T2DM that
was associated with NAFLD might also reﬂect differences in the
number and type of covariates that have been adjusted for
(Table 1).
Although there is now convincing evidence that NAFLD
increases risk of T2DM, and there is emerging evidence that this
risk varies according to NAFLD severity, further evidence is
unquestionably needed in non-Asian populations, as all of the
studies summarized in Table 1 are in various Asian populations,
and most of the evidence obtained to date has been obtained in
South Korean people. In addition, since the adjustment for poten-
tial confounders has been often incomplete, further prospective
studies with a larger panel of established diabetes risk factors
will be needed to ﬁrmly establish an independent contribution
of NAFLD to the development of T2DM.
Although NAFLD is strongly associated with obesity, insulin
resistance and T2DM, many people with NAFLD are not obese,
and many people with NAFLD do not have T2DM.
Consequently, as also shown in Table 1, we investigated the clus-
tering of NAFLD, insulin resistance and obesity in people who
developed incident T2DM. Speciﬁcally, we compared the impact
of obesity, insulin resistance (estimated by homeostasis model
assessment) and fatty liver (as detected by ultrasonography) on
the risk of incident T2DM at 5-year follow-up in a cohort of over
12,000 South Korean individuals [43]. These data showed that
each of these three risk factors was independently associated
with increased T2DM risk, and each risk factor (independently)
was associated with an approximate doubling of the T2DM risk
after adjustment for other recognized risk factors. When all three
risk factors occurred together in the same individual (and this
occurred in 50% of people with incident T2DM at follow-up),5 vol. 62 j S47–S64 S49
Poor nutrition
(e.g., high fat, high
carbohydrate, high
fructose)
Genetic factors
(e.g., PNPLA3
genotype)
Lipid globules/
steatosis
LCFAs/
DAGs
ceramides
Di-P PATAGs
Stellate and Kupffer
cells activation
Lipotoxicity
Inflammation, oxidative
stress, insulin resistance,
increased collagen matrix
Inflammation/fibrosis,
cirrhosis and HCC
Poor nutrition
(e.g., high fat, high
carbohydrate, high
fructose)
Genetic factorsIntestine (dysbiosis)
Primary
bile acids
Secondary
bile acids
Visceral ectopic fat, adipose tissue inflammation and type 2 diabetes
LCFAs, hyperinsulinaemia
Adipocytokines
Fig. 1. The inﬂuences of visceral ectopic fat accumulation, adipose tissue inﬂammation, type 2 diabetes, diet and intestinal dysbiosis to promote the development of
progressive liver disease in NAFLD. Visceral ectopic fat accumulation, which often occurs with inﬂammation and type 2 diabetes, causes resistance to insulin action and
hepatic necro-inﬂammation (by Kupffer cell activation) with activation of hepatic stellate cells and increased production of collagen matrix and progression of liver disease.
Progression of liver disease over an ill-deﬁned period of time causes advanced liver ﬁbrosis, cirrhosis and, in some cases, hepatocellular carcinoma. Poor diet (particularly
high fat and high fructose intakes) along with genetic factors (e.g., PNPLA3 polymorphisms) may also play a role in NAFLD progression increasing hepatic lipid accumulation
and increasing risk of liver ﬁbrosis. Alternations in the diet may cause dysbiosis of the gut microbiota with hepato-toxic effects from secondary bile acids. Dysbiosis may
alter the production of short-chain fatty acids (from fermentation of dietary carbohydrate), and increase the production of lipopolysaccharide into the portal circulation
(from egress of intestinal bacteria caused by increased intestinal permeability). Such effects create a pro-inﬂammatory hepatic stimulus that increases risk of progression of
NAFLD. (DAG, di-acylglycerol; HCC, hepatocellular carcinoma; LCFAs, long-chain fatty acids; PNPLA3, patatin-like phospholipase domain-containing 3).
Reviewthere was a fourteen-fold increase in risk of T2DM after adjust-
ment for potential confounders. Notably, in the same observa-
tional cohort of Korean people, we further investigated the
effect of resolution of fatty liver on risk of incident T2DM at 5-
year follow-up to try and establish whether NAFLD improve-
ments were associated with a risk reduction in incident T2DM.
Interestingly, these data showed that there was a signiﬁcant
reduction in risk of incident T2DM in those subjects in whom fat-
ty liver on ultrasound resolved over time. In particular, in those
subjects, risk of incident T2DM decreased to the background risk
of someone who had never had fatty liver [52]. Conversely, the
individuals in whom the severity of fatty liver worsened over
5 years (from mild to moderate/severe) showed a marked
increase in risk of incident T2DM [adjusted-OR 6.13 (95% CI
2.56–14.68) p <0.001 compared with the risk in people with
resolution of fatty liver], supporting the notion that more severe
forms of NAFLD are associated with higher risk of incident T2DM.
Rarelywhen studying the relationship betweenNAFLD and risk
of T2DM, has NAFLD been conﬁrmed, or severity assessed, by liver
histology [23]. In a landmark paper from 2006, in a 13.7-year fol-
low-up of 129 patients with biopsy-proven NAFLD, 42 patients
with NASH at baseline returned for follow-up biopsy and of these,
30 patients (71%) had T2DM (diagnosed by either fasting glucose/
2-h glucose level during an oral glucose tolerance test or by a clin-
ical history of diabetes). Of the patients with simple steatosis atS50 Journal of Hepatology 201baseline, 21 (46%) had T2DM and this difference was statistically
signiﬁcant (p = 0.01), suggesting that patients with NASH have a
higher risk of T2DM than those with simple steatosis.
Whether currently available biomarkers for NAFLD severity
are useful for monitoring NAFLD progression (or regression) in
people with T2DM is uncertain. Recently, the investigators of
the Edinburgh Type 2 Diabetes Study investigated ﬁve non-inva-
sive biomarkers to detect liver ﬁbrosis and determined the level
of agreement between them in 831 middle-aged patients with
T2DM [53]. Patients underwent ultrasound assessment to diag-
nose the presence or absence of fatty liver. Additionally, mea-
surements of the AST/ALT ratio, aspartate to platelet ratio index
(APRI), Enhanced Liver Fibrosis panel (ELF), Fibrosis-4 score
(FIB4) and liver stiffness measured by Fibroscan were undertak-
en. Based on data from the scientiﬁc literature, these investiga-
tors established thresholds for each of the ﬁve biomarkers for
identifying liver ﬁbrosis and then determined the level of agree-
ment between the biomarkers to detect liver ﬁbrosis in patients
with T2DM. Agreement between the top 5% of the distribution
for each biomarker pair was poor. APRI and FIB4 had the best
positive agreement at 76.4%, but agreement for all of the other
serum biomarker pairs was between 18% and 34%. Agreement
with the liver stiffness measurement was also poor (9–16%).
Using the top 5% of each biomarker there was good agreement
between the biomarkers to exclude the presence of advanced5 vol. 62 j S47–S64
Table 1. Studies of associations between incident type 2 diabetes mellitus and a) incident fatty liver, b) existing (prevalent) fatty liver, c) increasing severity of fatty liver and d) resolution of fatty liver, diagnosed
by non-invasive imaging only.
Study and year Study design, 
sample size, 
population and 
mean follow up
Diagnosis of 
NAFLD
Diagnosis of diabetes Regression modelling 
adjustments
Risk (HR, RR, OR) 
[95%CIs] for incident 
diabetes with incident 
NAFLD
Risk (HR, RR, OR) 
[95%CIs] for incident 
diabetes with prevalent, 
or existing  NAFLD
Risk (HR, RR, OR) 
[95%CIs] for incident  
diabetes with worsening 
of, or more severe 
NAFLD
Risk (HR, RR, OR) 
[95%CIs] for incident 
of diabetes with 
resolution of NAFLD
Yamada et al. 2010 
[42]
Retrospective
12,375
Japanese
5 years
Ultrasound IFG = fasting glucose 6.1-7.0 
mmol/L 
Diabetes = fasting glucose level 
≥7.0 mmol/L
Adjusted for age, body 
mass index (BMI), 
elevated blood pressure 
or hypertension, alcohol 
drinking,  smoking status
n.a. ORs for impaired fasting 
glucose or diabetes OR 
1.91 [1.56-2.34] men OR 
2.15 [1.53-3.01] women
n.a. n.a.
Sung et al. 2012 
[43]
Retrospective 
12,853
Korean
5 years
Ultrasound Self-report of diabetes, or 
medical history, or fasting 
plasma glucose during follow-up
Adjusted for age and sex, 
alcohol, smoking status, 
exercise, and educational 
status, triglyceride, ALT
n.a. OR 2.73 [1.38-5.41] n.a. n.a.
Shibata et al. 2007 
[44]
Case/control
3189
Japanese
4 years
Ultrasound Adjusted for age and BMI n.a. HR 5.5 [3.6-8.5] n.a. n.a.
Okamoto et al. 2003 
[45]
Prospective 
840
Japanese
10 years
Ultrasound 
Fasting glucose level ≥7.0 mmol/L 
or 2-h post-load plasma glucose 
level ≥11.1 mmol/L on a 75-g oral 
glucose tolerance test 
Fasting glucose ≥6.1 mmol/L or 
hemoglobin A1c (HbA1c) ≥6.5%
Age, sex, fasting glucose, 
HbA1c, BMI change during 
follow up, frequency of 
examinations, alcohol, 
family history diabetes
n.a. OR 1.83 [0.95-3.51] n.a. n.a.
Kim et al. 2008 [46] Retrospective
5372
Korean 
5 years
Ultrasound Fasting glucose level 
≥7.0 mmol/L or treatments for 
diabetes.
Age, sex, family history of 
diabetes, smoking, blood 
pressure, fasting glucose, 
BMI, HDL-C, triglyceride, 
ALT
n.a. RR 1.51 [1.04-2.20] RR 2.29 [1.13-4.63] 
(excluding frequent 
drinkers = >3x/week)
n.a.
Fan et al. 2007 [47] Case/control design
1146
Chinese
7 years
Ultrasound Self reported use of diabetes 
medications and WHO criteria 
(1999) 
Matched for age, sex, 
occupation, duration of 
follow up
n.a. OR 4.63 [3.0-7.0] n.a. n.a.
Bae et al. 2011 [48] Retrospective
7949
Korean 
4 years
Ultrasound Fasting glucose ≥7 mmol/L or 
HbA1C ≥6.5%
Adjusted for age, sex, 
smoking status, blood 
pressure, impaired 
fasting glucose, alcohol 
consumption, physical 
activity, BMI, HDL-C, 
triglycerides
n.a. HR 1.33 [1.07-1.66] n.a. n.a.
Park et al. 2012 [49] Prospective
25,232 
Korean
Men only
5 years
Ultrasound Self-report, or medical history, 
or fasting plasma glucose, or 
HbA1c ≥6.5% during follow-up
Adjusted for baseline age, 
sex, waist circumference, 
insulin and glucose 
(HOMA-IR), triglyceride, 
HDL-C, systolic blood 
pressure, creatinine, 
hsCRP, family history of 
diabetes, exercise, MetS
n.a. Mild fatty liver
HR 1.09 [0.81-1.48]
Moderate to severe fatty 
liver HR 1.73 [1.00-3.01]
n.a.
(continued on next page)
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Table 1 (continued)
Study and year Study design, 
sample size, 
population and 
mean follow up
Diagnosis of 
NAFLD
Diagnosis of diabetes Regression modelling 
adjustments
Risk (HR, RR, OR) 
[95%CIs] for incident 
diabetes with incident 
NAFLD
Risk (HR, RR, OR) 
[95%CIs] for incident 
diabetes with prevalent, 
or existing  NAFLD
Risk (HR, RR, OR) 
[95%CIs] for incident  
diabetes with worsening 
of, or more severe 
NAFLD
Risk (HR, RR, OR) 
[95%CIs] for incident 
of diabetes with 
resolution of NAFLD
Kasturiratne et al. 
2013 [50]
Retrospective 
2984
Sri Lankan 
3 years
Ultrasound Defined as a past history of 
diabetes mellitus or fasting 
glucose level >6.9 mmol/L (125 
mg/dl) at baseline.
Adjusted for age, sex, 
family history of diabetes, 
waist circumference, 
hypertension, 
dyslipidemia, impaired 
fasting glucose, ALT, BMI
n.a. HR 1.64 [1.20-1.23] n.a. n.a.
Chang et al. 2013 
[51]
Retrospective 
38,291
Korean
5 years
Ultrasound  
severity 
of NAFLD 
assessed 
with NAFLD 
fibrosis score.
Self-report, or medical history, 
or fasting glucose level, or 
HbA1c ≥6.5% during follow-up
Adjusted for baseline age, 
sex, waist circumference, 
insulin and glucose 
(HOMA-IR), triglyceride, 
HDL-C, systolic blood 
pressure, hsCRP, 
creatinine, family history of 
diabetes, exercise, MetS
n.a. Mild fatty liver 
HR 2.00 [1.79-2.24]
Intermediate and severe 
fatty liver 
HR 4.74 [3.67-6.13]
n.a.
Sung et al. 2013 
[52]
Retrospective 
13,218
Korean
5 years
Ultrasound Self-report, or medical history, 
or fasting glucose level during 
follow-up
Adjusted for baseline 
age, sex, BMI, glucose, 
insulin, baseline 
triglyceride, HDL-C, 
systolic blood pressure, 
alcohol, smoking, physical 
activity, and change in 
BMI between baseline 
and follow up ALT, AST 
and GGT
OR 2.49 [1.49-4.14] Fatty liver at baseline 
and fatty liver at follow up
OR 2.95 [1.91-4.54]
Fatty liver at baseline and 
worsening in severity at 
follow up OR 7.38 [3.36- 
16.22]
OR 0.95 [0.46-1.96]
n.a., not available.
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ﬁbrosis, but poor agreement to diagnose advanced ﬁbrosis. Thus,
further research is clearly needed to ﬁnd tools/tests for monitor-
ing disease progression (or resolution) in people with NASH and
T2DM, who are at highest risk of developing serious liver disease
(namely cirrhosis, liver failure and HCC).Diabetes development in NAFLD: pathophysiology
When imbalance occurs between energy intake and energy
expenditure, or when there is an intrinsic problem with storing
excess energy as lipid (triacylglycerol) in adipose tissue depots,
lipid occurs in other organs throughout the body. When lipid
occurs in tissues or organs not designed to accumulate fat, e.g.,
liver or omentum, the term ‘ectopic fat accumulation’ is often
used to infer that lipid accumulation has occurred in another site
besides adipose tissue [54].
NAFLD is an example of ectopic fat accumulation and this lipid
accumulation is usually associated with increased secretion of
hepatokines [55], increased gluconeogenesis, decreased glycogen
synthesis and inhibition of insulin signaling [56,57]. When excess
hepatic lipid accumulates, it often causes insulin resistance and
chronic inﬂammation increasing risk of progressive liver disease
with ﬁbrosis, cirrhosis and increased risk of HCC (Fig. 1). Besides
liver lipid metabolism, it is now clear that adipose tissue dysfunc-
tion/inﬂammation is crucial in NAFLD pathogenesis and increas-
ing evidence is also now suggesting that dysbiosis of the gut
microbiota plays a key role in regulating several intra-hepatic
metabolic and inﬂammatory pathways that contribute to the
development and progression of NAFLD. This is possibly through
the increased intestinal absorption of multiple bacterial products,
such as short-chain fatty acids (e.g., butyrate, propionate and
acetate), lipopolysaccharide and endotoxins. For detailed reviews
of the role of hepatic lipid accumulation and the gut microbiota
in inﬂuencing insulin resistance and inﬂammation in NAFLD,
see the following reviews [54,58,59]. Because of the constraints
on space, this review will only consider brieﬂy the mechanisms
that are potentially involved in the pathogenesis of insulin resis-
tance and inﬂammation in NAFLD.
Although obesity is strongly associated with hepatic steatosis,
excess body fat accumulation is not ‘a conditio sine qua non’ for
developing NAFLD. In fact, patients with lipodystrophy have
marked insulin resistance and commonly develop hepatic steato-
sis and T2DM, strongly suggesting that it is not body fat mass per
se that is important, but it is adipose tissue dysfunction that is a
key contributor to the pathogenesis of NAFLD [60]. Speciﬁcally,
increased free fatty acid (FFA) ﬂuxes from the adipose tissue pool
increase the availability of long-chain fatty acyl-CoAs for hepatic
lipid accumulation, particularly in physically inactive individuals
[58], and evidence is accumulating that hepatic lipid accumula-
tion is capable of causing hepatic/peripheral insulin resistance
and promoting hepatic inﬂammation [54,58].
Expansion of peripheral adipose depots provides buffering
capacity that may protect the liver from the excessive FFA ﬂuxes
that promote hepatic lipid accumulation. Within hepatocytes,
long-chain fatty acids (LCFAs) are esteriﬁed with glycerol-3-phos-
phate (derived from glycolysis) to form mono-acylglycerols, di-a-
cylglycerols (DAG) and tri-acylglycerols (TAG) (Fig. 2). Lipid
synthesis may increase production of intermediates, such as
DAG, di-palmitoyl phosphatic acid (Di-P PA) and other lipid prod-
ucts, such as ceramides; the increased production of these lipidJournal of Hepatology 201products (particularly DAGs) is very important in causing ‘resis-
tance’ within the hepatic insulin signaling pathway [61], promot-
ing hepatic inﬂammation [62–65] and increasing risk of
progressive liver disease that occurs with NASH. In the liver, pro-
duction of ceramides utilizes LCFAs [66], and ceramides can accu-
mulate into the cells via threemain routes: 1) the hydrolysis of the
membrane phospholipid sphingomyelin, which is coordinated by
the enzyme sphingomyelinase; 2) de novo synthesis from LCFAs
such as palmitate and serine; and 3) a ‘salvage’ pathway that uti-
lizes sphingosine and forms ceramide [67,68]. Although in the
past, it was thought that ceramide was simply a structural mole-
cule, there is some evidence that an increase in membrane cera-
mide cause insulin resistance (see review [69] and Fig. 2).
The production of DAG has been implemented as a cause of
hepatic insulin resistance and the conversion from TAG to DAG
is mediated by adipose triglyceride lipase (ATGL). Comparative
Gene Identiﬁcation-58 (CGI-58) is an activator of ATGL and DAG
activates protein kinase Ce (PKCe) membrane translocation to
inhibit the insulin receptor kinase and decrease insulin signaling
[70] (Fig. 2). Hepatic lipids that are not esteriﬁed also induce
endoplasmic reticulum stress, leading to the activation of c-Jun
N-terminal kinases and NF-jB [71], which are two major regula-
tors of inﬂammatory pathways that also inhibit phosphorylation
of insulin receptor substrate-1 (IRS-1) [72], potentially aggravat-
ing hepatic insulin resistance and increasing intra-hepatic cyto-
kine production (Fig. 2). Synthesis of lipids such as DAGs is
intimately related to inﬂammatory pathways, and DAGs may also
contribute to hepatic production of inﬂammatory cytokines [e.g.,
tumour necrosis factor-a (TNF-a), interleukin-6 (IL-6)], and pro-
coagulant factors [e.g., factor VIII, plasminogen activator inhibi-
tor-1 (PAI-1)]. Additionally, intestinal microbiota dysbiosis, per-
haps induced by alterations in the diet (Fig. 1), may affect other
hepatic lipid pathways, such as those involving bile acid metabo-
lism, consequently increasing hepatic inﬂammation and ﬁbrosis,
and resulting in an increased risk of developing cirrhosis and HCC.
To date, it is unclear whether improvements in NAFLD may
ameliorate risk of T2DM or improve glycaemic control in people
with NAFLD who have developed T2DM, but it is plausible that
resolution of liver fat and improvements in liver lipid metabolism
might modify the risk of T2DM via a liver-speciﬁc effect. Such a
liver-speciﬁc effect could be mediated by alteration in the secre-
tion of multiple hepatokines [55] or inﬂammatory cytokines that
inﬂuence risk of diabetes. In NAFLD, secretion of diabetogenic
hepatokines, such as retinol binding protein (RBP)-4, fetuin-A,
ﬁbroblast growth factor (FGF)-21; or inﬂammatory biomarkers
such as C-reactive protein (CRP), TNF-a and IL-6 [73] may directly
affect risk of incident T2DM by adversely affecting hepatic gluco-
neogenesis, glycogen synthesis [56,57] and insulin signaling [74].NAFLD, CVD and other cardiac diseases: epidemiology
NAFLD and CVD
Patients with NAFLD usually have features of the metabolic syn-
drome (MetS) and also have a myriad of other emerging CVD risk
factors [18,75,76]. This ﬁnding has important clinical implica-
tions for the development of future CVD events among these
patients.
A recent comprehensive meta-analysis of 27 cross-sectional
studies reported a strong association between NAFLD detected5 vol. 62 j S47–S64 S53
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Fig. 2. Lipid induced mechanisms contributing to hepatic insulin resistance and inﬂammation in NAFLD. Synthesis of lipid intermediates from long-chain fatty acids
(LCFAs), e.g., ceramide, lyso-phosphatidic acid, phosphatidic acid (PA), di-acylglycerol (DAG), tri-acylglycerol (TAG) and very-low-density lipoprotein (VLDL) secretion.
Synthesis of various species of DAG in particular may promote hepatic insulin resistance and inﬂammation. Synthesis of ceramide may also increase resistance to insulin
action by decreasing efﬁcient insulin signaling. (AGAT, acyl glycerol acyl transferase; AGPAT, acylglycerol phosphate acyltransferase; CGI-58, Comparative Gene
Identiﬁcation-58; Cytochrome P450 2E1; CYP 2E1; DGAT, di-acyl glycerol acyl transferase; IKKb, IjB kinase b; IRS-2-P, insulin receptor substrate-2 phosphorylation; JNK, c-
Jun N-terminal kinase; LPA, lysophosphatidic acid; GPAT, glycerol-3-phosphate acyltransferase; MAG, mono-acyl glycerol; mTOR, mechanistic target of rapamycin; mTORC-
2, mechanistic target of rapamycin complex-2; PA, phosphatidic acid; PAP, phosphatidate phosphohydrolase; PKCe, protein kinase Ce; TGRLPs, triglyceride-rich
lipoproteins).
Reviewby imaging or biopsy and several markers of subclinical
atherosclerosis, such as increased carotid intima-media thickness
(16 studies), increased coronary artery calciﬁcation (7 studies),
impaired ﬂow-mediated vasodilation (7 studies) and arterial
stiffness (6 studies). All of these associations were independent
of classical CVD risk factors and MetS features across a wide
range of patient populations [77]. Recently, in a cohort of 755
consecutive otherwise healthy adult men, Moon et al. also report-
ed a strong and independent association between NAFLD and car-
otid artery inﬂammation (which may reﬂect plaque
vulnerability), as evaluated by 18F-ﬂuorodeoxyglucose positron
emission tomography [78].
Several large cross-sectional population and hospital-based
studies, involving both patients without diabetes and those with
diabetes, have consistently shown that the prevalence of clinical
CVD is increased in patients with NAFLD (for more detailed
reviews see [75,76,79]). For example, in a national-based cohort
of over 11,000 United States adults, NAFLD was associated with
an increased prevalence of CVD, independently of multiple CVD
risk factors [80]. Similarly, in a large outpatient-cohort study of
patients with T2DM, the prevalence of coronary, cerebrovascular
and peripheral vascular disease was greater among those with
NAFLD than among those without this disease, independently
of traditional CVD risk factors, medication use and diabetes-relat-
ed variables [81]. Finally, in patients referred for clinical coronary
angiography, NAFLD was independently associated with
increased severity of coronary artery disease [82–84].S54 Journal of Hepatology 201To date, there are about 20 retrospective and prospective
studies that have assessed the relationship between NAFLD diag-
nosed on biopsy or imaging and the risk of developing fatal and
nonfatal CVD events [23,24,80,82,85–98]. As summarized in
Table 2, most of these studies support the notion that CVD is a
serious threat to patients with NAFLD. In this table we did not
include the large population-based cohort studies that used
serum liver enzymes (i.e., surrogate markers of NAFLD) to diag-
nose NAFLD and that conﬁrmed that mildly elevated serum liver
enzyme levels were independent, long-term predictors of inci-
dent CVD both in men and in women [75,79].
With regard to biopsy-diagnosed NAFLD (as shown in Table 2)
[23,24,88–90,97,98], some retrospective studies with reasonably
long follow-up have clearly shown that all-cause, CVD and liv-
er-related mortality were signiﬁcantly higher in NAFLD patients
than in matched control populations. These studies have also
shown that the presence and severity of hepatic ﬁbrosis is the
main determinant of all-cause and cause-speciﬁc mortality, and
that CVD is a very common cause of mortality among these
patients. Interestingly, some of these studies also reported that
patients with NASH, but not those with simple steatosis, had
[23,88] an increased risk of all-cause and CVD mortality com-
pared with the reference population. However, it should be noted
that all of these studies were retrospective cohort studies with
relatively small numbers of patients, who were seen at tertiary
care referral centers and full adjustment for potential con-
founders was not possible. Undoubtedly, all these features limit5 vol. 62 j S47–S64
Table 2. Principal prospective and retrospective studies of the risk of CVD mortality and morbidity in patients with NAFLD (deﬁned by biopsy or imaging only).
Study and year Study design, sample size, population and mean follow up Diagnosis of 
NAFLD
Main findings
Ekstedt M et al. 2006 [23] Retrospective cohort 
129 Swedish NAFLD patients, 13.7 years
Biopsy* Patients with NASH, but not those with simple steatosis, had higher rates of all-cause (~2-fold), CVD 
(~2-fold) and liver-related (~10-fold) mortality than the general population matched for age and sex
Ekstedt M et al. 2014 [24] Retrospective cohort 
229 Swedish NAFLD patients, 26.4 years 
Biopsy* NAFLD patients had increased risk of death (HR 1.29, 95% CI 1.04-1.59), with a high risk of death 
from CVD (HR 1.55, 95% CI 1.11-2.15) and liver-related disease (HR 3.2, 95% CI 1.05-9.81). 
NAFLD activity score (NAS) was not able to predict all-cause death, whereas fibrosis stage 
predicted all-cause, CVD and liver-related death 
Stepanova M et al. 2012 [80] 
and Lazo M et al. 2011 [91]
National-based cohort 
11,371 US adults from the Third National Health and Nutrition Examination 
Survey 1988-94, 14.5 years
Ultrasound* No significant association between NAFLD and all-cause and cause-specific (CVD, cancer and 
liver) mortality
Wong VW et al. 2011 [82] Prospective cohort
465 Chinese patients with coronary heart disease as diagnosed by 
coronary angiography, 1.8 years
Ultrasound|| NAFLD was independently associated with an increased prevalence of CVD at baseline but there 
was no significant association between NAFLD and risk of incident CVD events
Zhou YJ et al. 2012 [85] Community-based cohort 
3543 Chinese adult individuals, 4 years
Ultrasound* Patients with NAFLD had ~3-fold higher rates of all-cause and CVD mortality than those without NAFLD
Treeprasertsuk S et al. 2012 
[86]
Retrospective community-based cohort 
309 US NAFLD patients, 11.5 years
Ultrasound/
computed 
tomography¶
Framingham risk score accurately predicted the higher 10-year coronary heart disease risk in 
NAFLD patients and was the only variable significantly associated with the risk of developing new-
onset coronary heart disease events in this patient cohort 
Targher G et al. 2007 [87] Prospective cohort 
2103 Italian outpatients with type 2 diabetes without viral hepatitis and CVD 
at baseline, 6.5 years
Ultrasound§ NAFLD was associated with an increased risk of fatal and nonfatal CVD events (HR 1.87, 95% CI 
1.2-2.6), independently of age, sex, body mass index, smoking, diabetes duration, hemoglobin A1c, 
LDL-cholesterol, metabolic syndrome features, medication use
Söderberg C et al. 2010 [88] Retrospective cohort 
118 Swedish NAFLD patients, 24 years
Biopsy* Patients with NASH, but not those with simple steatosis, had higher rates of all-cause (~2-fold), 
CVD (~2-fold) and liver-related mortality than the general population matched for age and sex
Rafiq N et al. 2009 [89] Retrospective cohort
173 US NAFLD patients, 13 years 
Biopsy* CVD, cancer and liver-related complications were the most common causes of mortality in this 
cohort of NAFLD patients
Matteoni CA et al. 1999 [90] Retrospective cohort
132 US NAFLD patients, 18 years
Biopsy* Patients with NASH had higher rates of all-cause and liver-related mortality than those without the 
disease. CVD mortality did not differ between the groups
Kim D et al. 2013 [92] National-based cohort study 
11,154 US adults from the Third National Health and Nutrition Examination 
Survey, 14.5 years
Ultrasound and 
advanced fibrosis 
score systems *
NAFLD was not associated with increased all-cause mortality. However, NAFLD with advanced 
hepatic fibrosis (defined by NAFLD fibrosis score, APRI index or FIB-4) was independently 
associated with a 69% increased risk of all-cause mortality. Increase in mortality was almost entirely 
from CVD causes (for NFS: HR 3.46, 95% CI 1.91-6.25; for APRI: HR 2.53, 95% CI 1.33-4.83; for 
Jepsen P et al. 2003 [93] Retrospective cohort 
1804 Danish hospitalized patients with NAFLD, 6.2 years
FIB-4: HR 2.68, 95% CI 1.44-4.99) 
Ultrasound*  Patients with NAFLD had higher rates of all-cause (2.6-fold), CVD (2.1-fold) and liver-related (19.7-
fold) mortality than the general population
Haring R et al. 2009 [94] Population-based cohort 
4160 German individuals, 7.3 years
Ultrasound* NAFLD was associated with an increased risk of all-cause and CVD (HR 6.22, 95% CI 1.2-31.6) 
mortality in men, independently of age, sex, waist circumference, alcohol consumption, physical 
activity, civil status, equalized income, functional comorbidity index, blood pressure, diabetes status
Hamaguchi M et al. 2007 [95] Community-based cohort 
1637 Japanese individuals, 5 years
Ultrasound‡ NAFLD was associated with an increased risk of nonfatal CVD events (HR 4.10, 95% CI 1.6-10.7), 
independently of age, sex, body mass index, alcohol intake, smoking history, LDL-cholesterol and 
metabolic syndrome features 
Dunn MA et al. 2013 [96] Retrospective cohort 
2343 US type 2 diabetics seen in the primary care and specialty clinics of a 
large integrated delivery network, 5 years
Computed 
tomography§
No significant association was found between NAFLD and risk of all-cause mortality and cause-
specific (CVD, cancer and liver) mortality and morbidity. NAFLD patients (steatosis >30% on 
imaging) averaged 8 years younger than those without NAFLD
Dam-Larsen S et al. 2004 [97] Retrospective cohort
109 Danish NAFLD patients (without NASH at baseline), 16.7 years
Biopsy* No significant difference in mortality rates between patients with simple steatosis and the  
general population
Adams LA et al. 2005 [98] Retrospective cohort
420 US NAFLD patients, 7.6 years
Biopsy/imaging* Patients with NAFLD (especially those with cirrhosis and NASH) had higher rates of all-cause, CVD 
and liver-related mortality than the age and sex-matched general population
⁄Study outcome was all-cause and cause-speciﬁc mortality.
Study outcome was nonfatal coronary heart disease and stroke.
§Study outcome was a combined end point of CVD mortality and nonfatal myocardial infarction, ischemic stroke and coronary revascularization procedures.
||Study outcome was a combined end point of CVD mortality and nonfatal myocardial infarction and coronary revascularization procedures.
–Study outcome was a combined end point of CVD mortality and nonfatal congestive heart failure, angina, myocardial infarction and coronary revascularization procedures.
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the generalizability of the ﬁndings to a broader patient
population.
With regard to imaging-diagnosed NAFLD [80,82,85–87,91–
96], several large prospective studies have consistently shown
that NAFLD is associated with an increased risk of fatal and non-
fatal CVD events, independently of established CVD risk factors
both in individuals with, and without T2DM. In contrast, and sur-
prisingly, two recent studies, using data from the Third National
Health and Examination Survey (NHANES-III) database of over
11,000 United States adults, have reported that NAFLD was sig-
niﬁcantly associated with increased CVD prevalence but did not
predict the risk of all-cause and cause-speciﬁc mortality over
14 years of follow-up [80,91]. The results of these studies may
have been inﬂuenced by the inclusion of individuals with mild
hepatic steatosis within the control arm. Interestingly, however,
the latest analyses of the same NHANES-III database found that
NAFLD with advanced hepatic ﬁbrosis (deﬁned by non-invasive
scoring systems) was independently associated with a 70%
increased risk of all-cause mortality, and that this increase in
mortality was almost entirely due to CVD causes [92]. A meta-
analysis published in 2011 concluded that patients with NAFLD
(diagnosed by imaging or biopsy) had a twofold higher risk of
fatal and non-fatal CVD events (OR 2.05, 95% CI 1.81–2.31) than
the matched control population, but that the severity of NAFLD
histology did not further increase CVD mortality [6]. However,
further larger and longer follow-up studies in patients with biop-
sy-conﬁrmed NAFLD are needed in order to improve understand-
ing and establish whether NAFLD severity affects risk of CVD
events. It is important to note that similar to those studies inves-
tigating the relationship between NAFLD and diabetes, many of
these studies have not been able to adjust for a full range of
potential life-style factors and co-morbidities that would have
varied among studies but may have impacted on the study
results. For example, certain life-style factors may have had a
positive effect on NAFLD (e.g., coffee intake, Mediterranean diet).
Additionally, the management of certain co-morbidities may also
have had a positive effect on NAFLD (e.g., angiotensin converting
enzyme inhibitor or angiotensin II receptor blockers as treat-
ments for hypertension, statins for dyslipidaemia, and gluca-
gon-like peptide-1 agonists for T2DM). In addition, lifetime
smoking and alcohol intake are not usually considered in many
studies that have examined relationships between NAFLD and
extra-hepatic disease outcomes.
NAFLD and abnormalities in myocardial metabolism, cardiac function
and structure
It is now becoming increasingly evident that NAFLD is associated
with abnormalities in myocardial metabolism; for a more
detailed review see [79].
Using cardiac magnetic resonance imaging (MRI), Perseghin
et al. ﬁrstly reported that nonobese, nondiabetic, normotensive,
young individuals with NAFLD had impaired myocardial energy
metabolism (i.e., a lower phosphocreatine/adenosine triphos-
phate ratio, as measured by 31P-magnetic resonance spec-
troscopy [MRS]) and excessive fat accumulation in the
epicardial area compared with matched control subjects without
NAFLD. Interestingly, these myocardial metabolic alterations
were detected despite normal left ventricular (LV) morphological
features and systolic and diastolic functions [99]. Lautamaki et al.
[100] and Rijzewijk et al. [101] found that T2DM patients withS56 Journal of Hepatology 201higher intra-hepatic fat content on 1H-MRS had increased
myocardial insulin resistance and decreased myocardial perfu-
sion compared with those with lower intra-hepatic fat content;
additionally, myocardial insulin resistance was more severe
among those with higher intra-hepatic fat content even after
adjustment for potential confounders. Again, Rijzewijk et al.
[102] found that those with higher intra-hepatic fat content
had signiﬁcantly higher myocardial fat content (i.e., cardiac
steatosis). Interestingly, in this study cardiac steatosis was a
strong predictor of LV diastolic dysfunction [102].
To date, there are plentiful data linking NAFLD with abnor-
malities in cardiac structure and function both in adolescents
and in adults with, or without, co-existing MetS features [79].
For instance, in a small case-control study examining cardiac sta-
tus by MRI and 31P-MRS in adults with 1H-MRS-diagnosed
NAFLD, Hallsworth et al. [103] have reported signiﬁcant changes
in cardiac structure and evidence of early LV diastolic dysfunction
compared with age-, sex- and body mass index-matched controls,
in the absence of cardiac metabolic changes or overt cardiac dis-
ease. In a study of T2DM adults without history of CVD and
known hepatic diseases, Bonapace et al. [104] found that early
features of LV diastolic dysfunction could be detected by tissue
doppler imaging in those with NAFLD, even if the LV morphology
and systolic function were preserved. In addition, there was a
positive, graded relationship between the ultrasonographic
severity of NAFLD and diastolic dysfunction, independently of
hypertension, glycaemic control and other co-existing CVD risk
factors [104]. Furthermore, in a community-based cohort of
1886 Korean adults, Kim et al. found that ultrasound-diagnosed
NAFLD was associated with LV diastolic dysfunction, indepen-
dently of MetS features and other established CVD risk factors
[105].
Interestingly, and most importantly, similar ﬁndings have
been conﬁrmed also in pediatric NAFLD. Indeed, a number of
case-control studies reported that overweight or obese children
with NAFLD had echocardiographic features of early LV dysfunc-
tion compared with their counterparts without NAFLD [106–
110]. These myocardial functional abnormalities were indepen-
dent of multiple CVD risk factors. Notably, in the study by
Paciﬁco et al. [110] when the group of obese children was divided
according to the presence of NASH, it was evident that some
functional cardiac differences were more pronounced in those
with NASH. These observations are intriguing and need to be fur-
ther investigated. It is important to understand, for example,
whether hepatic necro-inﬂammation or ﬁbrosis per semight have
a stronger association with the cardiac phenotype than any other
hepatic alterations. This is important because it is remarkable
that these myocardial changes occur long before the onset of cir-
rhosis and portal hypertension, suggesting that the cardiac alter-
ations may not be the consequence of the changes in intra-
hepatic haemodynamic conditions.
Overall, therefore, from the above-mentioned published stud-
ies it is plausible to assume that patients with NAFLD have early
changes in myocardial substrate metabolism (e.g., impaired high-
energy phosphate metabolism, insulin resistance), producing car-
diac functional and structural consequences (e.g., LV dysfunction
and hypertrophy) that are potentially linked to an increased risk
of congestive heart failure (HF) in this group of patients. With
regards to this, two large population-based cohort studies that
used elevated serum liver enzymes for diagnosing NAFLD have
recently shown that this disease is independently associated with5 vol. 62 j S47–S64
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an increased incidence of HF [111,112]. However, further follow-
up studies in well-characterized cohorts of NAFLD patients are
needed to better examine the individual contribution of NAFLD
to the increased incidence of HF.NAFLD, cardiac arrhythmias and aortic valve sclerosis
Recently, mildly elevated liver transaminases have been shown
to be independently associated with increased incidence of atrial
ﬁbrillation (AF) in the Framingham Heart Study cohort [113]. A
similar link between elevated serum liver enzymes (mainly
serum GGT level) and AF risk was shown in a larger prospective
community-based study of 9333 subjects with a mean follow-
up of 12 years [114]. More direct evidence of increased risk of
AF associated with NAFLD has been recently reported by our
group [115,116]. In a case-control study, we found that ultra-
sound-diagnosed NAFLD was associated with an increased preva-
lence of AF in hospitalized patients with T2DM and this
association was independent of several clinical AF risk factors
[115]. In a prospective study, we found that T2DM patients with
NAFLD were more likely to develop incident AF over 10 years of
follow-up than their counterparts without NAFLD, and that ultra-
sound-diagnosed NAFLD was associated with a ﬁvefold increased
risk of incident AF, independently of MetS features and other
common AF risk factors [116].
Interestingly, recent data [117] have shown that NAFLD is also
independently linked with prolonged QTc interval, i.e., a powerful
predictor of ventricular arrhythmias and sudden cardiac death
[118,119], which might explain in part the increased CVD mor-
tality associated with NAFLD. Additionally, in a small study of
people without diabetes with histologically proven, non-cirrhotic
NAFLD, and an age-, sex- and body mass index-matched control
group, there was evidence of cardiac autonomic dysfunction, pre-
senting as orthostatic hypotension, vasovagal syncope or a rela-
tive nocturnal hypotension [120].
Finally, the presence of aortic valve sclerosis, i.e., a progressive
disease that shares multiple pathogenic risk factors with CVD and
is associated with an increased risk of CVD mortality [121,122],
has also been linked with NAFLD, independently of established
CVD risk factors, in both diabetic and nondiabetic individuals
[123,124].
Collectively, as discussed below, although not all data are
methodologically solid and most of the studies lack an histo-
logical diagnosis of NAFLD, the concept of NAFLD as being an
independent contributor to the development of atherosclerosis
and other structural and functional cardiac alterations, which
subsequently lead to clinical CVD, seems sufﬁciently substantiat-
ed by the current evidence to integrate it in the clinical approach
of both the patient with NAFLD and the patient with CVD.NAFLD and chronic kidney disease: epidemiology
The possible link between NAFLD and CKD has recently attracted
considerable scientiﬁc interest [1,125,126].
Several large cross-sectional population and hospital-based
studies, involving both adults without diabetes and patients with
diabetes, have shown that the prevalence of CKD (deﬁned as
either decreased estimated glomerular ﬁltration rate [GFR] and/or
overt proteinuria) is increased in people with NAFLD [127–136].Journal of Hepatology 201These studies have used either ultrasonography or biopsy to diag-
nose NAFLD and have excluded patients with end-stage renal dis-
ease, cirrhosis and those with known causes of chronic liver
disease (alcohol abuse, viral hepatitis and use of hepato-toxic
drugs in all studies and also hemochromatosis and autoimmune
hepatitis in some studies). In these studies, the prevalence of
CKD in patients with NAFLD ranged from approximately 20–55%
compared to 5–35% in patients without NAFLD. Importantly, most
of these studies, including those that used liver biopsy to diagnose
NAFLD, reported that the presence and severity of NAFLD was
associated with CKD stages, independently of established car-
dio-renal risk factors [133–136]. These data have been extensively
reviewed by our group elsewhere [125,126].
To date, there is a paucity of published data regarding the risk
of developing CKD in patients with NAFLD. As summarized in
Table 3, four observational studies with reasonably long follow-
up have assessed the relationship between NAFLD and the risk
of incident CKD [137–140]. In all studies, patients with overt cir-
rhosis or secondary causes of chronic liver diseases were exclud-
ed. In addition, in the two studies published by our group, no
participants had ultrasonographic ﬁndings suggestive of cirrhosis
[137,140].
It is important to note that in all these studies, NAFLD was
diagnosed by ultrasonography and the investigators have used
a creatinine-based GFR estimating equation instead of a direct
GFR measurement to deﬁne CKD. The use of direct measurements
of GFR should be encouraged as the creatinine-based equations
are not accurate in estimating GFR, especially for patients with
severe obesity or cirrhosis [141]. As shown in Table 3, it is also
important to note that the investigators have used varying
degrees of baseline adjustments for potential confounders.
None of these published studies have speciﬁcally assessed
whether a change in NAFLD status (either development of new
fatty liver, progression to cirrhosis, or resolution of existing fatty
liver) during the follow-up period modiﬁed the risk of incident
CKD. Finally, no detailed information is available in these studies
about speciﬁc renal pathology/morphology associated with
NAFLD. Notwithstanding these limitations, the published
prospective studies [137–140] have consistently reported an
independent association between NAFLD and increased risk of
incident CKD with HRs for CKD that ranged from approximately
1.3–1.9.
Very recently, in a well-conducted systematic review and
meta-analysis (63,902 participants, 20 cross-sectional and 13
longitudinal studies included), Musso et al. [7], conﬁrmed that
NAFLD as diagnosed by histology, imaging or liver enzyme eleva-
tion was signiﬁcantly associated with an increased risk of preva-
lent (OR 2.12, 95% CI 1.69–2.66) and incident CKD (HR 1.79, 95%
CI 1.65–1.95). Additionally, NASH was associated with a higher
prevalence (OR 2.53, 95% CI 1.58–4.05) and incidence (HR 2.12,
95% CI 1.42–3.17) of CKD than simple steatosis [7].
However, further longer prospective studies in larger cohorts
of patients with biopsy-proven NAFLD are needed to conﬁrm the-
se ﬁndings, and to determine whether improvement in NAFLD
(or future treatments for NAFLD) ultimately will prevent or delay
the development and progression of CKD. Moreover, because
CKD has many potential causes, it also will be of great interest
to characterize the renal injury manifestations associated with
NAFLD and clarify, in the future, whether NAFLD may selectively
contribute to the pathogenesis of different types of kidney
disease.5 vol. 62 j S47–S64 S57
Table 3. Principal prospective and retrospective studies of the risk of developing CKD in patients with NAFLD (deﬁned by imaging only).
Study and year Study design, sample size, population and 
follow up
Diagnosis of 
NAFLD
Main findings
Targher G et 
al. 2008 [137]
Prospective cohort 
1760 Italian outpatients with type 2 diabetes 
with preserved kidney function (mean 
baseline eGFR 94 ± 10 ml/min/1.73 m2) and 
not proteinuria, who did not have baseline 
CVD, cirrhosis or viral hepatitis 
6.5 years
Ultrasound* 547 subjects developed incident CKD. Cumulative 
incidence of CKD was significantly higher in those with 
NAFLD than in those without NAFLD (48% vs. 29%). 
NAFLD was associated with increased risk of incident of 
CKD (HR 1.49, 95% CI 1.1-2.2) independently of sex, age, 
body mass index, waist circumference, blood pressure, 
smoking status, diabetes duration, hemoglobin A1c, 
triglycerides, HDL-cholesterol, LDL-cholesterol, baseline 
eGFR, and use of medications
Chang Y et al. 
2008 [138]
Community-based cohort 8329 non-
diabetic and non-hypertensive Korean 
men with normal kidney function (median 
baseline eGFR 79 ml/min/1.73 m2) and not 
proteinuria at baseline
3.2 years
Ultrasound* 324 subjects developed incident CKD during follow-up. 
NAFLD was associated with increased risk of incident 
of CKD (HR 1.60, 95% CI 1.3-2.0), independently of 
age, body mass index, alcohol consumption, blood 
pressure, smoking status, fasting glucose, baseline 
eGFR, triglycerides, HDL-cholesterol, LDL-cholesterol, 
insulin resistance, C-reactive protein, and incident cases 
of hypertension and diabetes. Consistent results were 
observed in all subgroups analysed
Arase Y et al. 
2011 [139]
Retrospective cohort 5561 Japanese 
patients with NAFLD and no CKD at 
baseline (mean eGFR 75 ± 12 ml/min/1.73 
m2 and not overt proteinuria)
5.5 years
Ultrasound* 263 subjects developed incident CKD during follow-
up. Among patients with NAFLD, elevated serum 
gamma-glutamyltransferase level was associated with 
increased risk of incident of CKD (HR 1.35, 95% CI 
1.02-1.8), independently of age, sex, hypertension, 
diabetes, total cholesterol, triglycerides, HDL-cholesterol, 
aminotransferases, gamma-glutamyltransferase, 
hemoglobin, white blood cells, platelets, baseline eGFR
Targher G et 
al. 2014 [140]
Prospective cohort 261 Italian adult 
outpatients with type 1 diabetes with 
preserved kidney function (mean baseline 
eGFR 92 ± 23 ml/min/1.73 m2) and not 
macroalbuminuria, who did not have 
baseline CVD, cirrhosis or viral hepatitis 
5.2 years
Ultrasound* 61 subjects developed incident CKD during follow-up. 
Cumulative incidence of CKD was significantly higher 
in those with NAFLD than in those without NAFLD 
(35% vs. 11%). NAFLD was associated with increased 
risk of incident of CKD (HR 1.85, 95% CI 1.03-3.3), 
independently of age, sex, diabetes duration, hemoglobin 
A1c, hypertension, baseline eGFR, microalbuminuria. 
Addition of NAFLD to traditional cardio-renal risk factors 
improved the discriminatory capability of the regression 
models for predicting incident CKD
⁄Study outcome was new-onset CKD deﬁned as occurrence of estimated glomerular ﬁltration rate (eGFR) <60 ml/min/1.73 m2 [eGFR was estimated by using the MDRD
(Modiﬁcation of Diet in Renal Disease) Study equation] and/or overt proteinuria.
ReviewNAFLD, cardiovascular/cardiac diseases and CKD:
pathophysiology
It is beyond the scope of this brief review to discuss in detail the
pathophysiological links between NAFLD, cardiovascular/cardiac
complications as well as the links between NAFLD and CKD.
Detailed discussions of this topic have been published elsewhere
[75,76,79,125,126,142]. To date, there is uncertainty as to
whether NAFLD is simply a marker or a mediator (pathogenic fac-
tor) of cardiovascular/cardiac diseases and CKD. Moreover, uncer-
tainty also exists about the prognostic value of NAFLD in risk
stratiﬁcation for CVD and CKD.
However, although larger, long-term prospective studies are
needed, we consider that increasing evidence supports the asser-
tion that NAFLD is not simply a marker but also a pathogenic fac-
tor (and probably both) of vascular/cardiac and kidney damage.
From the data available in the literature, the association of
NAFLD with CKD and especially that with CVD seems to have
strength, consistency, speciﬁcity, temporality and biological plau-
sibility, satisfying many of the established criteria for a causal
relationship.S58 Journal of Hepatology 201In respect to mechanisms how NAFLD impacts on cardiovas-
cular/cardiac diseases and CKD, it is important to underline that
a clear understanding of the pathophysiological pathways that
link NAFLD to the development and progression of these extra-
hepatic complications remains lacking because of the intricate
biological interactions between NAFLD, visceral obesity and insu-
lin resistance. NAFLD, cardiovascular/cardiac diseases and CKD
share many metabolic features and risk factors, leading to the
concept that they belong to a complex multisystem disease with
several organ manifestations and a complex interplay between
the different diseases, with multiple bidirectional cause-effect
relationships. The speciﬁc contribution of one disease to the
others is therefore difﬁcult to discern, and there might be sub-
stantial inter-individual variability.
It is likely that there is a pathogenic ‘‘cross-talk’’ between the
liver and the expanded and ‘dysfunctional’ (inﬂamed) adipose tis-
sue [1,18,58,72,75]. As schematically shown in Fig. 3, the putative
underlying mechanisms that link NAFLD, CKD, CVD and other
cardiac diseases probably have their origin in expanded and
inﬂamed visceral adipose tissue. This adipose tissue secretes mul-
tiple factors that are potentially involved both in the5 vol. 62 j S47–S64
↑ Free fatty acids
↑ Inflammatory cytokines
↓ Adiponectin
↑ Insulin resistance
Expanded and dysfunctional
adipose tissue
NAFLD
Myocardial steatosis and
increased pericardial fat
Fatty kidney and increased
renal sinus fat
↑ Inflammatory cytokines
↑ Insulin resistance
↑ Inflammatory cytokines
↑ Insulin resistance
Insulin resistance
Dysglycemia
↑ Insulin resistance
↑ Glucose production
↑ FGF-21
↑ Fetuin-A
Atherogenic 
dyslipidemia
↑ Triglycerides 
↓ HDL-cholesterol
↑ Small, dense LDL-C
↑ Post-prandial lipemia
Inflammation
Oxidative stress
↑ CRP
↑ IL-6
↑ TNF-α
↑ Reactive oxigen species
Hypercoagulability
Hypofibrinolysis 
↑ Fibrinogen 
↑ Factor VIII
↑ Tissue factor
↑ PAI-1
Arterial
hypertension
↑ Angiotensinogen 
↑ Endothelin-1
↑ TGF-β
Cardiac autonomic
dysfunction
Structural electrical
remodeling
Cardiovascular disease 
Aortic valve sclerosis
Cardiac dysfunction 
Cardiac hypertrophy 
Congestive heart failure
Cardiac
arrhythmias
Chronic kidney
disease
Expanded and dysfunctional
adipose tissue
Fig. 3. Schematic representation of the putative mechanisms underlying the contribution of NAFLD to the increased risk of cardiovascular disease (CVD), chronic
kidney disease (CKD) and other structural and arrhythmic cardiac complications. The complex and intertwined interactions among NAFLD, abdominal obesity and
insulin resistance make it extremely difﬁcult to dissect out the speciﬁc role of the liver and the underlying mechanisms responsible for the association between NAFLD and
the risk of developing CVD, CKD and other structural cardiac complications (i.e., aortic valve sclerosis, cardiac dysfunction/hypertrophy, congestive heart failure and atrial
ﬁbrillation). NAFLD might be associated with such complications either as a consequence of shared cardio-metabolic risk factors and co-morbidities or as a marker of
ectopic fat accumulation in other organs. For instance, myocardial steatosis and increased pericardial fat volume as well as fatty kidney and increased renal sinus fat volume
may exert local adverse effects that result in structural and functional derangements of the myocardium and kidneys. However, in this dangerous and intricate scenario,
growing evidence indicates that NAFLD is not only a simple marker of vascular/cardiac and kidney damage but also may play a part in the pathophysiology of CVD, CKD and
other cardiac complications. Indeed, NAFLD may directly contribute to the development and progression of these vascular/cardiac complications through the hepatic
production of lipids, atherogenic lipoproteins, the induction of hepatic/peripheral insulin resistance and dysglycaemia (i.e., increased hepatic glucose production), and the
systemic release of numerous potentially pathogenic mediators (i.e., pro-inﬂammatory biomarkers, pro-oxidant molecules, and pro-coagulant and pro-ﬁbrogenic factors).
(CRP, C-reactive protein; FGF-21, ﬁbroblast growth factor-21; HDL, high-density lipoprotein; LDL-C, low-density lipoprotein cholesterol; PAI-1, plasminogen activator
inhibitor-1; TNF, tumour necrosis factor).
JOURNAL OF HEPATOLOGYatherogenesis and in the development of insulin resistance and
NAFLD [54,58,71,72,75,143–145]. As brieﬂy discussed above
when considering the link between NAFLD and T2DM, emerging
evidence also suggests that altered gut microbiota can inﬂuence
the development and progression of NAFLD, possibly through
the increased intestinal absorption of multiple bacterial products
[59]. In this complex situation, the liver may function both as the
target organ of the resulting systemic abnormalities and the
source of several pathogenic mediators that may amplifyJournal of Hepatology 201vascular/cardiac and kidney damage. Indeed, NAFLD, especially
its necro-inﬂammatory variant (NASH), may exacerbate hepatic/
peripheral insulin resistance, cause atherogenic dyslipidemia,
and release a myriad of pro-inﬂammatory molecules and vasoac-
tive and thrombogenic molecules that play important roles in the
pathophysiology of cardiovascular/cardiac diseases and CKD
[1,18,75,125,126,143–146]. In this dangerous scenario (as also
depicted in Fig. 3), emerging evidence also suggests that the
coexistence of obesity-related increases in fat accumulation in5 vol. 62 j S47–S64 S59
Table 4. Putative targeted screening measures in high-risk individuals for the assessment of cardiovascular disease (CVD) risk among patients with diagnosed
NAFLD.
Assessment of the coexisting risk factors Physical examination Laboratory tests
A Prior history of myocardial infarction, angina, 
heart failure, stroke or other clinical CVD 
manifestations (i.e., patients in secondary 
prevention for CVD)
Body weight
Height
Body mass index
Waist circumference
Blood pressure
Arterial bruits and pulse examination 
(including ankle brachial pressure index)
Total cholesterol
Triglycerides
HDL cholesterol
LDL cholesterol
Fasting glucose
Hemoglobin A1c (HbA1c)
Estimated glomerular filtration rate 
(serum creatinine)
Urinalysis
Albuminuria
Fasting insulin (for calculating HOMA-
estimated insulin resistance, principally 
in non diabetics) 75-g oral glucose 
tolerance test (in patients with impaired 
fasting glycaemia and/or obesity)
CVD risk estimation (by using risk cal-
culators, e.g., Framingham risk score 
or QRISK2)
Carotid artery ultrasonography (in most 
cases) or high resolution computed    
tomography coronary artery calcium 
score
B Family history for premature ischemic heart 
disease (i.e., age of onset <55 years for men 
and <65 years for women in first-degree  
relatives) or type 2 diabetes 
C Cigarette smoking 
D Diabetes mellitus (i.e., fasting glucose level 
≥7 mmol/L or HbA1c ≥6.5% or 
2-h glucose level ≥11.1 mmol/L during a 
75-g OGTT or a “random” glucose level 
≥11.1 mmol/L in presence of hyperglycaemic 
symptoms)
E Hyperlipidemia (principally hypercholeste-
rolemia or atherogenic dyslipidemia; if LDL 
cholesterol >4.9 mmol/L exclude presence 
of familial hypercholesterolemia)  
F    Hypertension (i.e., blood pressure ≥140/90 
mmHg or on treatment)
G   Obesity (i.e., for Europeans: BMI ≥30 kg/m2 
and/or waist circumference ≥102 cm in men 
and ≥88 cm in women)
H Metabolic syndrome (i.e., based on the 2009 
definition proposed by the International 
Diabetes Federation and the American Heart 
Association/National Heart, Lung, and Blood 
Institute)
I Chronic kidney disease (i.e., eGFR <60 ml/
min/1.73 m2 and/or abnormal albuminuria)
All patients with NAFLD should be screened for CVD risk, and the assessments should be periodically repeated (every 1 to 2 years), depending on the clustering of CVD risk
factors. Most of these clinical and laboratory data along with sex and age can be useful in clinical practice for the estimation of the global (total) CVD risk by using risk
assessment systems based on either the Framingham risk score or other available risk score calculators such as QRISK2. However, the use of these CVD risk score calculators
needs to be validated by future studies in larger cohorts of NAFLD patients of various ethnic backgrounds in order to substantiate their clinical relevance as a foundation for
the primary prevention of CVD in this group of patients. In general, current management of the CVD risk among NAFLD patients widely overlaps with the guidelines for the
treatment of CVD risk factors, which are adopted for the general adult population.
Reviewthe myocardium/pericardium and kidney may additionally exert
local adverse effects that result in structural and functional
derangements in the myocardium, kidney and vasculature.
Conclusions
The last decade has been an exciting one for investigators and
clinicians interested in understanding the broader consequences
of NAFLD for chronic liver disease, HCC and for extra-hepatic dis-
eases, such as type 2 diabetes, CVD and cardiac disease and CKD.
More frequently do patients with NAFLD die from extra-hepatic
complications of NAFLD (mainly from CVD causes) than liver dis-
ease per se and clearly with the epidemic of obesity and T2DM the
prevalence of NAFLD is likely to markedly increase. Table 4 sug-
gests putative targeted screening measures in high-risk indi-
viduals for the assessment of global CVD risk among patients
with diagnosed NAFLD [147].
There is now ﬁrm evidence that NAFLD is an important risk
factor for T2DM and there is increasing evidence that NAFLD
not only contributes to the development and progression ofS60 Journal of Hepatology 201CVD but also to cardiac diseases (e.g., LV dysfunction and hyper-
trophy, AF and heart valve calciﬁcation) and CKD. Further
research is needed to understand the biological mechanisms by
which NAFLD inﬂuences risk of HCC and these extra-hepatic dis-
eases not least to establish whether there are key ‘common
threads’ (e.g., insulin resistance and activation of inﬂammatory
pathways) that link NAFLD to the development of extra-hepatic
diseases.
An improved knowledge of the pathophysiological links
between NAFLD and these extra-hepatic complications will not
only help develop new pharmacological treatments for this liver
disease per se, but may also help decrease the global burden of
these very common non-communicable diseases that we now
know share a ‘common soil’ with NAFLD.Financial support
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